Alpha Teknova/$TKNO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alpha Teknova
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
- Ticker
- $TKNO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 158
- Headquarters
- Hollister, United States
- Website
- www.teknova.com
Alpha Teknova Metrics
BasicAdvanced
$486M
-
-$0.30
-
-
Price and volume
Market cap
$486M
52-week high
$9.48
52-week low
$1.91
Average daily volume
632K
Financial strength
Current ratio
3.563
Quick ratio
2.507
Long term debt to equity
0.418
Total debt to equity
0.451
Interest coverage (TTM)
-15.41%
Profitability
EBITDA (TTM)
-8.164
Gross margin (TTM)
36.43%
Net profit margin (TTM)
-34.76%
Operating margin (TTM)
-31.56%
Effective tax rate (TTM)
-0.31%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-8.96%
Return on equity (TTM)
-24.12%
Valuation
Price to revenue (TTM)
9.195
Price to book
7.08
Price to tangible book (TTM)
8.69
Price to free cash flow (TTM)
-66.182
Free cash flow yield (TTM)
-1.51%
Free cash flow per share (TTM)
-0.119
Growth
Revenue change (TTM)
15.45%
Earnings per share change (TTM)
-11.21%
3-year revenue growth (CAGR)
7.77%
3-year earnings per share growth (CAGR)
-39.64%
What the Analysts think about Alpha Teknova
Analyst ratings (Buy, Hold, Sell) for Alpha Teknova stock.
Analyst projections of the future price of Alpha Teknova stock.
Bulls say / Bears say
Preliminary third-quarter revenue was $12.5–$12.7 million, up 19–21% year on year, while gross margin was estimated at 36–38%. This points to continued sales momentum and better margins than a year earlier. (Alpha Teknova)
Teknova says its products support more than 70 therapies or diagnostics in clinical trials, and it expects at least one to reach commercialisation by the end of 2027. Purchases can rise substantially as programmes advance, creating a potential growth runway beyond current research orders. (StockAnalysis)
New Build-Tek and Fill-Tek tools let customers configure custom products more easily and order varied bag formats in a single lot. These capabilities could make Teknova more attractive as customers scale products from research towards clinical manufacturing. (Alpha Teknova, Alpha Teknova)
Teknova priced an offering of 8 million shares at $5 each, about 32% below the prior close, diluting existing holders; underwriters also have an option for extra shares. The need to raise equity while the share price is recovering may weigh on investor returns. (SEC, Investing.com)
The company remained loss-making in the first half of 2026, with a $7.7 million net loss and $13.2 million of borrowings at June. It also expected up to $8 million of free cash outflow for the full year, so profitability and self-funding remain unproven. (SEC, Alpha Teknova)
Growth remains exposed to uneven biopharma demand: management said cell and gene therapy orders were soft and biopharma revenue had been muted. The company also says biotech funding typically takes about four quarters to flow through to its sales, which could delay the expected recovery. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
Alpha Teknova Financial Performance
Revenues and expenses
Alpha Teknova Earnings Performance
Company profitability
Upcoming events
No upcoming events
Alpha Teknova News
AllArticlesVideos
Funds containing Alpha Teknova
Fund name | Fund size | $TKNO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.